FierceBiotech, 05. May 2017 Seattle kills off $2 billion Immunomedics deal amid revolt
Seattle Genetics has terminated a major drug tie-up with Immunomedics after intense legal battles, although a final say-so will need to come from the courts. This all goes back to February, when Immunomedics signed a potential $2 billion development and licensing deal with Seattle Genetics for IMMU-132, including a hefty $250 million upfront, only to have it placed on hold in March after a shareholder revolt.